5-Bromo-3'-(4-ethoxyphenyl)-1,2-dihydrospiro[indole-3,2'-[1,3]thiazolidine]-2,4'-dione

Catalog No. :
ACDCOX781
CAS No. :
946387-38-8
Molecular Formula :
C18H15BrN2O3S
Molecular Weight :
419.30

IUPAC Name:5-bromo-3'-(4-ethoxyphenyl)spiro[indoline-3,2'-thiazolidine]-2,4'-dione

5-Bromo-3'-(4-ethoxyphenyl)-1,2-dihydrospiro[indole-3,2'-[1,3]thiazolidine]-2,4'-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10g90%$770.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Bromo-3'-(4-ethoxyphenyl)-1,2-dihydrospiro[indole-3,2'-[1,3]thiazolidine]-2,4'-dione
IUPAC Name5-bromo-3'-(4-ethoxyphenyl)spiro[indoline-3,2'-thiazolidine]-2,4'-dione
MDL No.MFCD00955468
Molecular FormulaC18H15BrN2O3S
Molecular Weight419.30
SMILESO=C1NC2=C(C=C(Br)C=C2)C13SCC(N3C4=CC=C(OCC)C=C4)=O
InChI KeyUFBVAORQDUAOEO-UHFFFAOYSA-N
Synonym5-bromo-3'-(4-ethoxyphenyl)-1,2-dihydrospiro[indole-3,2'-[1,3]thiazolidine]-2,4'-dione;10-BROMO-3-(4-ETHOXYPHENYL)SPIRO[1,3-THIAZOLIDINE-2,3'-INDOLINE]-4,7-DIONE;Spiro[3H-indole-3,2'-thiazolidine]-2,4'(1H)-dione, 5-bromo-3'-(4-ethoxyphenyl)-;5-Bromo-3'-(4-ethoxyphenyl)spiro[indoline-3,2'-thiazolidine]-2,4'-dione
CAS No.946387-38-8

Synthetic Route by SureRoute

1. ACDCOX781 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACZDAR051 route compound structure diagram
    ACZDAR05122237-13-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDCOX781 route product structure diagram
    ACDCOX781946387-38-8
Inquiry

2. ACDCOX781 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACSZPC617 route compound structure diagram
    ACSZPC617637-56-9 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDCOX781 route product structure diagram
    ACDCOX781946387-38-8
Inquiry

Comments (0)